Imricor Medical Systems (ASX:IMR) started the VISABL-VT clinical trial after performing the first-in-human ventricular ablation guided by real-time interventional cardiac magnetic resonance (iCMR) at the Amsterdam University Medical Center, according to a Friday filing with the Australian bourse.
The trial evaluates the safety and effectiveness of radiofrequency ablation of ventricular tachycardia in ischemic cardiomyopathy using the Vision-MR Ablation Catheter 2.0 in the iCMR environment.
The patient was treated for both right-sided and left-sided premature ventricular complexes, the filing said.
Ventricular ablation is a procedure used to treat ventricular tachycardia, a rapid, abnormal heartbeat.
Price (AUD): $1.36, Change: $+0.18, Percent Change: +14.83%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.